Description

Genorise Recombinant Human H-FABP Protein Summary

Alternative names for H-FABP: Heart-type fatty acid binding protein (hFABP), FABP3

Product Specifications

Background: 

Heart-type fatty acid binding protein (hFABP) also known as mammary-derived growth inhibitor is a protein that in humans is encoded by the FABP3 gene.^[1] FABP3 gene contains four exons and its function is to arrest growth of mammary epithelial cells. This gene is also a candidate tumor suppressor gene for human breast cancer. H-FABP is a small cytoplasmic protein (15 kDa) released from cardiac myocytes following an ischemic episode.^[2] Like the nine other distinct FABPs that have been identified, H-FABP is involved in active fatty acid metabolism where it transports fatty acids from the cell membrane to mitochondria for oxidation.^[2]

H-FABP is a sensitive biomarker for myocardial infarction^[3] and can be detected in the blood within one to three hours of the pain. H-FABP is 20 times more specific to cardiac muscle than myoglobin,^[4]  H-FABP is recommended to be measured with troponin to identify myocardial infarction and acute coronary syndrome in patients presenting with chest pain. H-FABP measured with troponin shows increased sensitivity of 20.6% over troponin at 3-6 hours following chest pain onset.^[5]  Its rapid release into plasma after myocardial injury – 60 minutes after an ischemic episode,^[6] and its relative tissue specificity. Measuring H-FABP in combination with troponin increased the diagnostic accuracy and with a negative predictive value of 98% could be used to identify those not suffering from MI at the early time point of 3-6 hours post chest pain onset.^[5] The effectiveness of using the combination of H-FABP with troponin to diagnose MI within 6 hours is well reported.^[6] H-FABP also has prognostic value. Alongside D-dimer, NT-proBNP and peak troponin T, it was the only cardiac biomarker that proved to be a statistically significant predictor of death or MI at one year. Patients who were TnI negative but H-FABP positive had 17% increased risk of all cause mortality within one year compared to those patients who were TnI positive but H-FABP negative.^[7]  H-FABP has been proven to significantly predict 30 day mortality in acute pulmonary embolism.^[8] H-FABP is more effective than Troponin T in risk stratifying Chronic Heart Failure patients.^[9]

References

1. Phelan CM, et al. (1996). Genomics34(1): 63–8.
2. Kleine AH, et al. (1992). Molecular and Cellular Biochemistry116(1-2): 155–62.
3. Tanaka T, et al. (1991). Clinical Biochemistry24 (2):
4. Ghani F, et al. (2000). Clinical Chemistry46 (5): 718–9.
5. Glatz JF, et al. (1994).  British Heart Journal71 (2): 135–40.

1. Van Nieuwenhoven FA, et al. (1995). Circulation 92 (10): 2848–54.
2. Viswanathan K, et al. (2010). Journal of the American College of Cardiology 55: 2590–8.
3.  Kaczyñska A, et al. (2006). Clinica Chimica Acta; International Journal of Clinical Chemistry 371 (1-2): 117–23. .
4. Niizeki T, et al. (2007). Journal of Cardiac Failure 13 (2): 120–7.

Product Citations